Retatrutide vs Semaglutide and Tirzepatide: What the New Phase 3 Data Really Show

Retatrutide now has detailed Phase 3 data from TRIUMPH-2, giving researchers a clearer look at how a triple GIP/GLP-1/glucagon agonist performs in adults with type 2 diabetes and obesity or overweight.

The results are important not because they settle every comparison with semaglutide or tirzepatide, but because they move retatrutide further from early-stage promise toward a mature late-stage clinical evidence base.

Why retatrutide is different

Retatrutide is designed to activate three metabolic hormone pathways in a single molecule:

• GIP
• GLP-1
• glucagon

Semaglutide is a GLP-1 receptor agonist, while tirzepatide activates both GIP and GLP-1 receptors. Retatrutide adds glucagon receptor activity, making it a triple agonist.

Mechanistic differences alone do not prove clinical superiority. The meaningful question is what happens in randomized trials.

TRIUMPH-2: the key Phase 3 results

TRIUMPH-2 randomized 1,152 adults with type 2 diabetes and obesity or overweight to retatrutide 4 mg, 9 mg, 12 mg, or placebo for 80 weeks.

Under Lilly’s efficacy estimand, average body-weight changes were:

• 12.7% reduction with retatrutide 4 mg
• 19.1% reduction with retatrutide 9 mg
• 20.8% reduction with retatrutide 12 mg
• 4.0% reduction with placebo

Among participants with baseline BMI of 35 or greater, the 12 mg group lost an average of 23.4% of body weight.

More than half of participants in the 12 mg group no longer met BMI criteria for obesity by the end of the trial.

What happened to glycemic control?

A1C also improved substantially.

Average A1C reductions were 1.4 percentage points with 4 mg, 1.6 percentage points with 9 mg, and 1.5 percentage points with 12 mg, compared with 0.2 percentage points with placebo.

Up to 40.0% of participants reached an A1C below 5.7%.

Why cross-trial comparisons can be misleading

It is tempting to place retatrutide, semaglutide, and tirzepatide weight-loss percentages side by side and declare a winner.

That is not scientifically sound unless the drugs were tested head-to-head under the same protocol.

Different trials can vary in:

• baseline body weight
• diabetes status
• duration
• dose-escalation schedule
• background therapy
• estimand
• handling of discontinuations
• population characteristics

The stronger comparison will come from dedicated head-to-head trials.

A direct retatrutide-versus-semaglutide trial is underway

The Canadian Clinical Trial Search Portal lists TRANSCEND-T2D-2, a Phase 3 randomized study comparing once-weekly retatrutide with once-weekly semaglutide in adults with type 2 diabetes inadequately controlled on metformin, with or without an SGLT2 inhibitor.

That trial should provide much more useful comparative evidence than independent trial percentages.

What about retatrutide versus tirzepatide?

Retatrutide and tirzepatide differ mechanistically because retatrutide adds glucagon receptor activity to GIP and GLP-1 agonism.

However, mechanism should not be mistaken for an outcome.

Until sufficiently informative head-to-head data are available, claims that retatrutide is categorically “better” than tirzepatide should be treated cautiously.

Cardiometabolic effects beyond body weight

In TRIUMPH-2, Lilly also reported average reductions at the highest retatrutide dose in triglycerides, non-HDL cholesterol, systolic blood pressure, waist circumference, and high-sensitivity C-reactive protein.

These findings are scientifically important because obesity treatment is increasingly being evaluated through broader cardiometabolic outcomes rather than body weight alone.

Safety and tolerability

The most common adverse events were gastrointestinal, particularly diarrhea, nausea, constipation, decreased appetite, and vomiting.

Adverse-event discontinuation rates were 3.8%, 11.6%, and 7.7% in the 4 mg, 9 mg, and 12 mg groups respectively, compared with 4.9% with placebo.

Safety interpretation should continue to evolve as larger and longer studies are completed.

Why the wider retatrutide program matters

Retatrutide is being studied across multiple conditions, including obesity, type 2 diabetes, cardiovascular disease, kidney disease, knee osteoarthritis pain, chronic low-back pain, obstructive sleep apnea, weight maintenance, and metabolic liver disease.

This matters because the long-term value of metabolic therapies may ultimately be judged by effects on major health outcomes rather than weight loss alone.

Retatrutide is still investigational

Despite growing interest, retatrutide remains investigational and is not currently approved by regulatory agencies for public use.

The new Phase 3 results strengthen the evidence base, but regulatory review and additional clinical data remain necessary.

What the new evidence changes

TRIUMPH-2 does not answer every question about how retatrutide compares with semaglutide or tirzepatide.

What it does show is that triple agonism has now produced substantial weight and glycemic effects in a large Phase 3 population with type 2 diabetes and obesity or overweight.

The next important step is comparative evidence.

That is why direct trials such as TRANSCEND-T2D-2 may ultimately be more informative than cross-trial headline comparisons.

Frequently asked questions

What is retatrutide?

Retatrutide is an investigational once-weekly triple agonist that activates GIP, GLP-1, and glucagon receptors.

How much weight loss occurred in TRIUMPH-2?

Under the efficacy estimand, participants receiving 12 mg lost an average of 20.8% of body weight over 80 weeks.

Is retatrutide stronger than semaglutide?

Separate trial percentages cannot establish superiority. A dedicated Phase 3 retatrutide-versus-semaglutide trial is underway and will provide more meaningful comparative evidence.

Is retatrutide better than tirzepatide?

There is not enough direct comparative evidence to make that conclusion. Retatrutide has a different receptor profile, but mechanism does not by itself establish superior outcomes.

Is retatrutide approved?

No. Retatrutide remains investigational and is not approved for public use.

Sources

• Eli Lilly — TRIUMPH-2 Phase 3 results
• Canadian Clinical Trial Search Portal — TRANSCEND-T2D-2
• Eli Lilly — What to know about retatrutide

This article is for educational purposes and summarizes publicly available clinical-trial information. It is not medical advice.